ETView announced appointment of Javier Campos, MD, to its scientific advisory board
July 25, 2011, TEL AVIV, Israel‐‐ ETView Medical Ltd. (TASE: ETVW), a commercial‐stage medical device company traded on the Tel Aviv stock exchange, announced today the appointment of Javier Campos, MD, to its Scientific Advisory Board. Dr. Campos currently holds the positions of Clinical Professor, Executive Medical Director of Operating Rooms; Vice Chair, Clinical Affairs, and Director of Cardiothoracic Anesthesia for the University of Iowa. Dr. Campos has published over 42 peer‐reviewed scientific articles in the field of cardiothoracic anesthesia, with over 20 articles devoted to lung isolation surgical technique. Dr. Campos previously held clinical appointments at UCLA School of Medicine Department of Anesthesiology. Dr. Campos received his medical training at the Autonomous University, Guadalajara, Mexico, and performed his residency at the State General Hospital, Hermosillo, Sonora, Mexico. Dr. Campos holds multiple professional society appointments, including American Society of Anesthesiologists, International Anesthesia Research Society, and the Society of Cardiovascular Anesthesiologists.
Dr. Campos is a member of the editorial board of the Journal of Cardiothoracic and Vascular Anesthesia.
William Edelman, Co‐Chairman of the Board for ETView, commented, “We are thrilled to have Dr. Campos join our Scientific Advisory Board. Dr. Campos is an internationally respected clinician focused in the lung isolation surgical market. Dr. Campos will provide valuable counsel to ETView as we continue the commercial expansion worldwide for our VivaSight™ product line.” Mr. Edelman continued, “We intend to recruit other clinicians of Dr. Campos' caliber to join him in our Scientific Advisory Board over the next few months. "ETView's VivaSight™ combines high‐flow ventilation airway management with continuous video monitoring to overcome current limitations and associated adverse surgical events during lung isolation
About ETView, Medical, Ltd.
ETView Medical Ltd. (TASE: ETVW) has pioneered development of the VivaSight™ platform (previously known as TVT™), combining an airway ventilation tube with integrated, continuous, high‐resolution airway imaging for patient airway control and lung isolation capability (eliminating the need for fiberoptic bronchoscope1 imaging during these procedures).
VivaSight™‐SL, a single‐use disposable medical device consisting of a single‐lumen ventilation tube with an integrated, continuous, high‐resolution video imaging system is currently sold in Europe, Israel, and the US to overcome current limitations and associated adverse surgical events during lung isolation surgeries.2 It is estimated that over 1.9 million lung isolation procedures are conducted worldwide annually,3 accounting for over $250mm in single‐use medical disposables.4 Visit www.etview.com for additional information.
The Company estimations in this press release, including those estimations regarding the Company's predicted scope of business, constitute forward‐looking statements, as such term is defined under the Israeli Securities Law (5728‐1968), and there is no certainty that such estimations shall materialize. The Company's estimations are based on business assumptions, prior experience, and professional data. Due to various factors, foreseen and unforeseen, including, but not limited to, changes in market trends, competition, global or local economic conditions, and amendments of regulation, such estimations may not materialize in whole or in part, or materialize in a substantially different manner than anticipated by the Company.